Navigation Links
Cancer drugs in the pipeline
Date:12/11/2008

SAN ANTONIO - Scientists in the clinic and the laboratory continue to work to drive breast cancer mortality rates down with breakthrough drugs. With tamoxifen's discovery 30 years behind us, and the impact of Herceptin still being felt, researchers are studying zoledronic acid, aromatase inhibitors and monoclonal antibodies, among others, with encouraging results. Data will be presented at the CTRC-AACR San Antonio Breast Cancer Symposium.


Zoledronic Acid May Have Anti-Tumor Properties
Abstract #5101, Robert Coleman, M.D

Early results of the AZURE (Adjuvant Zoledronic Acid to Reduce Recurrence) trial suggest that zoledronic acid may have antitumor properties when combined with chemotherapy. Treatment was linked with a reduction in tumor size (20.5 mm vs. 30 mm), an increase in the complete response rate (10.9 percent vs. 5.8 percent) and a decrease in the number of patients requiring mastectomy (65.3 percent vs. 77.9 percent).

Full release available/Complete data to be presented at the meeting.


Breast Cancer Patients May have Better Option to Reduce Estrogen Levels
Abstract #15, Stephen Jones, M.D
Embargo: 10:15 a.m. CST, December 11, 2008

Despite adjuvant therapy to reduce estrogen levels, one in five breast cancer survivors will have a recurrence. The first results from the TEAM study, one of the largest clinical trials ever conducted for invasive breast cancer, demonstrated that exemestane may be more effective in postmenopausal women than current treatment with tamoxifen. Exemestane is an agent that actually stops the body from producing estrogen.

Full data to be presented at the meeting.


Herceptin Increases Event-Free Survival in Locally Advanced HER2-Postive Breast Cancer
Abstract #31, Luca Gianni, M.D

Among patients with HER2-positive, locally advanced breast cancer, neoadjuvant treatment with Herceptin increased three-year, event-free survival to 70 percent compared with 53 percent among those receiving chemotherapy alone. The addition of trastuzumab (Herceptin) was well tolerated with acceptable cardiac safety. Researchers claim this phase III clinical trial establishes chemotherapy with one year of Herceptin as a standard treatment option in this patient population.

Full data to be presented at the meeting.


Lapatinib Improved Progression-Free Survival in Postmenopausal Women with Breast Cancer
Abstract #46, Stephen Johnston, Ph.D

For the treatment of women with hormone-receptor-positive metastatic breast cancer that also co-expressed HER2, combining lapatinib with an aromatase inhibitor significantly improved progression-free survival from three months in the letrozole alone group to 8.2 months in the combination group. Overall clinical benefit rate increased from 28.7 percent to 48.7 percent. Involving 1,286 patients, this is the largest trial of its kind to date.

Full data to be presented at the meeting.


Adjuvant Aromatase Inhibitors Lower Breast Cancer Recurrence Risk
Abstract #12, James Ingle, M.D.
Embargo: 9:30 a.m. CST, December 11, 2008

Adjuvant therapy with aromatase inhibitors (AIs) for postmenopausal estrogen-receptor-positive breast cancer given either as initial monotherapy or after several years of tamoxifen decreases the risk of recurrent disease more than tamoxifen, according to two meta-analyses. The risk reduction with AIs was statistically significant.

Full data to be presented at the meeting.


'/>"/>

Contact: Jeremy Moore
Jeremy.moore@aacr.org
267-646-0557
American Association for Cancer Research
Source:Eurekalert

Related medicine news :

1. Combination of TYKERB(R) (lapatinib) Plus Letrozole Demonstrated Significant Improvement in Delaying Disease Progression for HER2+/ErbB2+ Post-Menopausal Metastatic Breast Cancer
2. Pilots May Face Greater Cancer Risk
3. Estrogen pills can benefit women with metastatic breast cancer
4. Light shines for potential early cancer diagnosis technique
5. LegalView Reports That Skin Cancer Drug May Offer Treatment to Mesothelioma Patients
6. PADRES Contra El Cancer to Host its 10th Annual Posada Holiday Celebration for Children with Cancer
7. UBC researchers discover gene mutation that causes eye cancer
8. Treadmill Desks More Effective in Decreasing Prostate Cancer Risks Than Vitamin and Antioxidant Supplements
9. Hormone therapy for prostate cancer does not appear to increase cardiac deaths
10. Oral cancer patients could be diagnosed earlier
11. PreMD Files Provisional Patent Application Describing a New Method of Quantifying Cancer Biomarkers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/6/2016)... CA (PRWEB) , ... February 06, 2016 , ... With ... and easily add warm color grades to their footage. A LUT is a Lookup ... pixel's color to the corresponding color indicated by the table. By manipulating each pixel, ...
(Date:2/5/2016)... Bethpage, NY (PRWEB) , ... February 05, 2016 , ... ... florist-quality long-stem roses in a variety of colors, assortments and packaging. This staple for ... at any King Kullen location. , For Valentine’s Day, not only are long-stem ...
(Date:2/5/2016)... ... February 05, 2016 , ... The event is being held on April 7, ... Minneapolis, Minn. Triumph Over Parkinson’s will fund nearly $100,000 for research for the care ... with Parkinson’s disease and is the architect of this informative event to raise awareness ...
(Date:2/5/2016)... ... February 05, 2016 , ... Freed-Hardeman University President ... have signed a joint enrollment and degree completion agreement. The agreement, which ... baccalaureate degrees at FHU|Dickson. , The agreement allows students to be jointly ...
(Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... ... independent PROSHRED franchises from across the country gathered at the La Valencia Hotel ... top performers. PROSHRED Chicago was named the year’s most outstanding franchise, walking ...
Breaking Medicine News(10 mins):
(Date:2/5/2016)... Feb. 5, 2016  ivWatch, a medical devices company, is ... Award granted by Governor Terry McAuliffe,s office. ivWatch ... February 25th at an event to be held at the ... award honors professionals and business that have made significant contributions ... Logo - http://photos.prnewswire.com/prnh/20160205/330117LOGO ...
(Date:2/5/2016)... 2016 http://www.researchandmarkets.com/research/jsc97m/global ... "Global Musculoskeletal Partnering 2010-2016: Deal trends, ... their offering. --> http://www.researchandmarkets.com/research/jsc97m/global ... "Global Musculoskeletal Partnering 2010-2016: Deal trends, ... their offering. --> Research ...
(Date:2/5/2016)... , Feb. 5, 2016 Dehaier Medical ... or the "Company"), which develops, markets and sells ... China and international markets, ... which aims to concentrate the Company,s resources to ... respiratory business and to focus more on its ...
Breaking Medicine Technology: